drugset / Trial / NCT00171613

A Study of Octreotide Depot vs Saline Control in Pediatric Hypothalamic Obesity Patients

NCT00171613

Phase 4 Completed 32 enrolled Novartis
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The extension protocol is designed to allow those patients randomized to placebo in the core portion of the protocol to receive a 6 month treatment of open label octreotide and allow those patients randomized to octreotide who appeared to benefit from treatment, to continue to receive octreotide.

Timeline

Start
2005-02
Primary completion
2005-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Octreotide Peptide